AstraZeneca’s Truqap Flops in Phase III Triple-Negative Breast Cancer Trial
Pictured: AstraZeneca's manufacturing facility in Sweden/iStock, Fotonen AstraZeneca on Tuesday announced that its AKT inhibitor Truqap (capivasertib), when used in combination with paclitaxel, failed to meet its primary efficacy endpoint in the …